Allogeneic NK T-Cells Expressing CD19 Specific CAR in B-Cell Malignancies

Phase 1 Unknown 36 enrolled Athenex, Inc.

Non-randomizedParallel-groupOpen-labelTreatment

This study is a multi-center study to evaluate the safety of KUR-502 in subjects with refractory/relapsed B-cell NHL or leukemia (ALL or CLL).

Evaluation	Drug	Modality	Dose	Route
Subject	KUR-502	Cell therapy	1e+07 unknown	Intravenous
Subject	KUR-502	Cell therapy	3e+07 unknown	Intravenous
Subject	KUR-502	Cell therapy	1e+08 unknown	Intravenous